您现在的位置: 论文资源库 >> 论文资源 >> 医药学论文 >> 药学论文 >> 正文

中药复方脂肝乐抗大鼠脂肪肝的作用>>lunwen.5151doc

中药复方脂肝乐抗大鼠脂肪肝的作用
作者:未知 文章来源:网络 点击数: 更新时间:2010-2-10

【关键词】  脂肪肝; 脂质过氧化作用; 中成药; 大鼠,Wistar; 脂肝乐

  [Abstract] Objective: To explore the curative effect of Chinese herbal compounds, Zhiganle to hepatic adiposis in rats induced by high fat diet, and to study its mechanism. Method: Wistar rats were randomly divided into 6 groups: Normal control (NC), pathological model (PM), Dongbaogantai treated group (DT), and 3 Zhiganle treatment groups that received different dosages of Zhiganle (ZT1 1.5 g·kg-1·d-1, ZT2 3.0 g·kg-1·d-1, and ZT3 4.5 g·kg-1·d-1). All the experimental rats except those in group NC, were given high fat diet for 12 weeks and then fed with normal diet. Began in the 13th week, rats in group DT were administered with Dongbaogantai(0.3 g·kg-1·d-1), and rats in groups ZT1, ZT2, and ZT3 received Zhiganle for other 12 weeks. Rats in NC were given normal saline instead. Finally, all the rats were executed, and their serum triglyceride (TG), serum total cholesterol (T-CH), hepatic TG, hepatic T-CH, glutathione (GSH), malonaldehyde (MDA) and hepatic pathological changes were checked. Results: Levels of serum TG, serum T-CH, hepatic TG, hepatic T-CH, and MDA were clearly higher (P<0.01 or P<0.05) and GSH level obviously lower (P<0.01 or P<0.05) in group PM than those in group NC; the levels of serum TG, serum T-CH, hepatic TG, hepatic T-CH, and MDA in treatment groups were clearly lower (P<0.01 and P<0.05) and GSH level in the liver remarkably higher (P<0.01 and P<0.05) than those in group PM. Hepatic pathological changes were lightened in treated groups than those in group PM. Conclusion: Zhiganle has good treating effects on hepatic adiposis in rats induced by high fat diet.

  [Key words] fatty liver; lipid peroxidation; ready-made patent drugs; rats,Wistar; Zhiganle

    脂肪肝是由多种疾病和原因引起的肝脏脂肪变性。国内外学者认为当肝细胞合成甘油三酯(TG)及分泌极低密度脂蛋白(VLDL)不平衡时,脂肪肝就会形成。对于脂肪肝的治疗,目前临床上尚缺乏较满意的药物。已报道的考来烯胺、烟酸肌醇酯、苯扎贝特、吉非罗齐等药物虽然可以从不同环节抑制脂肪肝,但不良反应多、疗程长,故临床应用受到限制[1]。根据传统中医理论活血化瘀、疏肝解郁、健脾化湿研制出的中药复方脂肝乐(简称ZGL)是由草决明、山楂、泽泻等多味中药组成,临床已试用于治疗脂肪肝患者,取得了较好疗效。由于营养因素在脂肪肝的发生发展中占有主要地位,因此,2005年9月~2006年3月采用高脂饲料诱导大鼠脂肪肝模型,观察了ZGL对脂肪肝的治疗作用并对其部分作用机制进行了探讨。

  1  材料与方法

  1.1  动物雄性Wistar大鼠,120只,体重(150±20)g,贵阳动物实验中心提供,合格证号:SCXK(黔)2002-0001。

  1.2 药品及试剂ZGL由内蒙古鄂尔多斯市第二人民医院提供,批号:020816,为棕色圆形颗粒制剂,临用前将颗粒研磨成粉末,用蒸馏水配制成所需浓度使用,溶液pH=6.5。东宝肝泰片,通化东宝药业股份有限公司生产,批准文号:吉卫药准字(1996)第430110号,配制方法同上。胆固醇(化学纯,进口分装),中国医药分公司北京采购供应站经销,批号020908。血清及肝脏生化指标检测试剂盒,北京中山生物技术有限公司生产。其余化学试剂均为分析纯。

  1.3  复制脂肪肝动物模型高脂饲料(玉米粉79.5%、猪油20.0%、胆固醇0.4%、胆盐0.1%), 动物自由取食,持续12周,复制大鼠脂肪肝动物模型。颈动脉放血法处死各组大鼠5只,取肝左叶同一部位组织,常规HE染色,光镜观察,脂变细胞占肝小叶的1/2~2/3或2/3以上,细胞增大或肿胀,胞浆内充满脂滴空泡,肝窦狭窄、极度狭窄甚至闭塞,表明造模成功。

  1.4  分组与给药  

  Wistar大鼠按体重随机分为6组:正常组、模型组及ZGL低剂量、中剂量、高剂量组和东宝肝泰组。除正常对照组外,其余各组均复制脂肪肝模型。12周后终止病因刺激,开始灌胃给药,ZGL低剂量、中剂量、高剂量为1.5、3.0、4.5 g·kg-1·d-1(分别相当于临床给药量的5倍、10倍、15倍),东宝肝泰组为0.3 g·kg-1·d-1(相当于临床给药量5倍),脂肪肝模型组和正常对照组每天灌服等容量的生理盐水,连续给药12周,实验结束时,动物禁食24 h,颈动脉放血法处死动物,取血清

——本文来自[论文资源库]lunwen.5151doc.com收集与整理,感谢原作者。
本文版权归原作者所有,如需转载或摘录请注明出处:论文资源库 http://lunwen.5151doc.com

论文录入:5151doc    责任编辑:5151doc 
【字体: 】【发表评论】【加入收藏】【告诉好友】【打印此文】【关闭窗口
| 设为首页 | 加入收藏 | 联系站长 | 在线投稿 | 版权申明 | 网站登陆 |